These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 2117053)

  • 21. Effect of selegiline on dopamine concentration in the striatum of a primate.
    Kaseda S; Nomoto M; Iwata S
    Brain Res; 1999 Jan; 815(1):44-50. PubMed ID: 9974121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modification of the striatal dopaminergic neuron system by carbon monoxide exposure in free-moving rats, as determined by in vivo brain microdialysis.
    Hara S; Mukai T; Kurosaki K; Kuriiwa F; Endo T
    Arch Toxicol; 2002 Oct; 76(10):596-605. PubMed ID: 12373456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of type A and B monoamine oxidase on the formation of 3,4-dihydroxyphenylacetic acid (DOPAC) in tissues from the brain of the rat.
    Garrett MC; Soares-da-Silva P
    Neuropharmacology; 1990 Oct; 29(10):875-9. PubMed ID: 2123970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoamine oxidase in pancreatic islets, exocrine pancreas, and liver from rats. Characterization with clorgyline, deprenyl, pargyline, tranylcypromine, and amezinium.
    Lenzen S; Nahrstedt H; Panten U
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Nov; 324(3):190-5. PubMed ID: 6419132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modification of dopamine release by selective inhibitors of MAO-B.
    Finberg JP; Lamensdorf I; Armoni T
    Neurobiology (Bp); 2000; 8(2):137-42. PubMed ID: 11061211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway.
    Aluf Y; Vaya J; Khatib S; Loboda Y; Finberg JP
    Neuropharmacology; 2013 Feb; 65():48-57. PubMed ID: 22982254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of selective monoamine oxidase (MAO) inhibitors on conditioned avoidance responses (CAR) of rats.
    Timár J; Knoll B; Gyarmati Z; Knoll J
    Pol J Pharmacol Pharm; 1979; 31(4):251-60. PubMed ID: 523335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different effects of monoamine oxidase inhibition on MPTP depletion of heart and brain catecholamines in mice.
    Fuller RW; Hemrick-Luecke SK; Kindt MV; Heikkila RE
    Life Sci; 1988; 42(3):263-71. PubMed ID: 3121972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Striatal dopamine metabolism in monoamine oxidase B-deficient mice: a brain dialysis study.
    Fornai F; Chen K; Giorgi FS; Gesi M; Alessandri MG; Shih JC
    J Neurochem; 1999 Dec; 73(6):2434-40. PubMed ID: 10582603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoamine oxidase inhibitors prevent striatal neuronal necrosis induced by transient forebrain ischemia.
    Matsui Y; Kumagae Y
    Neurosci Lett; 1991 May; 126(2):175-8. PubMed ID: 1922929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Age-dependent effects of the 2'-methyl analog of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: prevention by inhibitors of monoamine oxidase B.
    Finnegan KT; Irwin I; Delanney LE; Langston JW
    J Pharmacol Exp Ther; 1995 May; 273(2):716-20. PubMed ID: 7752075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selectivity of clorgyline and pargyline as inhibitors of monoamine oxidases A and B in vivo in man.
    Murphy DL; Lipper S; Slater S; Shiling D
    Psychopharmacology (Berl); 1979 Apr; 62(2):129-32. PubMed ID: 111275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic inhibition of monoamine oxidase reduces noradrenaline release in rat vas deferens and anococcygeus muscle.
    Hovevey-Sion D; Finberg JP
    Naunyn Schmiedebergs Arch Pharmacol; 1987 Jul; 336(1):70-6. PubMed ID: 3114651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microdialysis perfusion of COA-Cl enhances dopamine metabolism in the dorsal striatum of freely moving mice.
    Jamal M; Tsukamoto I; Takei S; Miki T; Kinoshita H; Takehiko M
    Acta Neurobiol Exp (Wars); 2024 Oct; 84(3):256-265. PubMed ID: 39392021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of type A and type B monoamine oxidase in the metabolism of released [3H]dopamine from rat striatal slices.
    Schoepp DD; Azzaro AJ
    Biochem Pharmacol; 1982 Sep; 31(18):2961-8. PubMed ID: 6814449
    [No Abstract]   [Full Text] [Related]  

  • 36. The effect of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline.
    Zsilla G; Földi P; Held G; Székely AM; Knoll J
    Pol J Pharmacol Pharm; 1986; 38(1):57-67. PubMed ID: 3020531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specificity of endogenous substrates for types A and B monoamine oxidase in rat striatum.
    Schoepp DD; Azzaro AJ
    J Neurochem; 1981 Jun; 36(6):2025-31. PubMed ID: 6787175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors.
    Wachtel SR; Abercrombie ED
    J Neurochem; 1994 Jul; 63(1):108-17. PubMed ID: 8207420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.
    Karoum F
    Br J Pharmacol; 1987 Feb; 90(2):335-45. PubMed ID: 3103805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation.
    Sader-Mazbar O; Loboda Y; Rabey MJ; Finberg JP
    Br J Pharmacol; 2013 Nov; 170(5):999-1013. PubMed ID: 23992249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.